Cargando…
Item-Level Investigation of Participant and Study Partner Report on the Cognitive Function Index from the A4 Study Screening Data
BACKGROUND: Greater subjective cognitive changes on the Cognitive Function Index (CFI) was previously found to be associated with elevated amyloid (Aβ) status in participants screening for the A4 Study, reported by study partners and the participants themselves. While the total score on the CFI rela...
Autores principales: | Amariglio, R.E., Sikkes, S.A.M., Marshall, G.A., Buckley, R.F., Gatchel, J.R., Johnson, K.A., Rentz, D.M., Donohue, M.C., Raman, R., Sun, C.-K., Yaari, R., Holdridge, K.C., Sims, J.R., Grill, J.D., Aisen, P.S., Sperling, R.A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8240963/ https://www.ncbi.nlm.nih.gov/pubmed/34101781 http://dx.doi.org/10.14283/jpad.2021.8 |
Ejemplares similares
-
The Computerized Cognitive Composite (C3) in A4, an Alzheimer’s Disease Secondary Prevention Trial
por: Papp, K.V., et al.
Publicado: (2021) -
Instrumental activities of daily living, amyloid, and cognition in cognitively normal older adults screening for the A4 Study
por: Marshall, Gad A., et al.
Publicado: (2020) -
Alzheimer’s Disease Clinical Trial Research Adaptation Following COVID-19 Pandemic Onset: National Sample of Alzheimer’s Clinical Trial Consortium Sites
por: Rhodus, Elizabeth K., et al.
Publicado: (2022) -
Inferior and medial temporal tau and cortical amyloid are associated with daily functional impairment in Alzheimer’s disease
por: Halawa, Omar A., et al.
Publicado: (2019) -
Predicting Amyloid Burden to Accelerate Recruitment of Secondary Prevention Clinical Trials
por: Langford, O., et al.
Publicado: (2020)